Coloplast A/S - Annual Report 2022/23 & Remuneration Report 2022/23
09 November 2023 - 7:32AM
Coloplast A/S - Annual Report 2022/23 & Remuneration Report
2022/23
FY 2022/23 organic growth of 8% and 28% EBIT margin1).
Reported revenue in DKK grew 9% to DKK 24,500 million
- Organic growth rates by business area: Ostomy Care 8%,
Continence Care 7%, Voice and Respiratory Care 10% (8 months),
Advanced Wound Care 7% (Advanced Wound Dressings 6%), and
Interventional Urology 10%.
- EBIT1) was DKK 6,845 million, down 1% from last year. The
EBIT margin1,2) was 28% against 31% last year, reflecting
inflationary headwind on input costs and an increase in operating
expenses which includes DKK 219 million from acquisition-related
amortisation cost.
- ROIC after tax and before special items was 17% against 27%
last year, negatively impacted by the Atos Medical and Kerecis
acquisitions. Diluted earnings per share (EPS) before special items
decreased by 6% to DKK 22.46, due to a 4% decrease in net profit,
mostly impacted by an increase in net financial expenses as a
result of the Atos Medical financing.
- The Board of Directors recommends a year-end dividend of DKK
16.00 per share, which brings the total dividend for the year to
DKK 21.00 per share, compared to DKK 20.00 per share last
year.
Acquisition of Kerecis finalised on 31 August
20233)
- The equity capital raise related to the financing of the
acquisition was completed on 30 August 2023. Coloplast issued 12.2
million new B shares, raising gross proceeds of approximately DKK
9.2 billion.
- For FY 2022/23, Kerecis delivered pro-rata revenues of DKK 772
million with revenue growth of around 50% and an EBIT margin of
around 6% (excluding PPA amortisation), in line with
expectations.
Sustainability highlights
- During FY 2022/23, Coloplast made progress on key ambitions,
including operating on 78% renewable energy in our own operations,
increasing the recycling rate of production waste to 75% and
reducing our scope 1 and 2 emissions by 10% since the base year
2018/19.
FY 2023/24 financial guidance – organic revenue growth
of around 8% and an EBIT margin of 27-28%
- The organic revenue growth assumes continued momentum across
business areas and regions. Reported growth in DKK is expected to
be around 12% and includes around 4%-points impact from the
acquisition of Kerecis (11 months) and limited negative impact from
currencies.
- The reported EBIT margin before special items is expected to be
27-28%. The EBIT margin includes around 100 basis points dilution
from Kerecis (incl. around DKK 100 million in PPA amortisation) and
negative impact from currencies.
- Capital expenditures are expected around DKK 1.4 billion. The
effective tax rate is expected to be around 22%.
1) Before special items of DKK 69 million in Q4 2022/23 and
before special items of DKK 74 million in FY 2022/23.2) Before
special items of DKK 36 million in Q4 2021/22 and DKK 471 million
in FY 2021/22.3) The terms of the transaction and the financial
assumptions stated in Coloplast's stock exchange announcement no.
03/2023 regarding the acquisition of Kerecis are unchanged and can
be found here: Acquisition of Kerecis
Please find our Annual Report 2022/23 and Remunation
Report 2022/23 in the links below.
For further information, please contact
Investors and analystsAnders
Lonning-SkovgaardExecutive Vice President, CFOTel. +45 4911
1111
Aleksandra DimovskaSenior Director, Investor RelationsTel. +45
4911 1800 / +45 4911 2458Email: dkadim@coloplast.com
Kristine Husted MunkSenior Manager, Investor RelationsTel. +45
4911 1800 / +45 4911 3266Email: dkkhu@coloplast.com
Press and mediaPeter MønsterSr. Media Relations
ManagerTel. +45 4911 2623Email: dkpete@coloplast.com
AddressColoplast A/SHoltedam 1DK-3050
HumlebaekDenmarkCompany reg. (CVR) no. 69749917
Websitewww.coloplast.com
This announcement is available in a Danish and an
English-language version. In the event of discrepancies, the
English version shall prevail.
Coloplast was founded on passion, ambition, and commitment. We
were born from a nurse’s wish to help her sister and the skills of
an engineer. Guided by empathy, our mission is to make life easier
for people with intimate healthcare needs. Over decades, we have
helped millions of people to live a more independent life and we
continue to do so through innovative products and services.
Globally, our business areas include Ostomy Care, Continence Care,
Advanced Wound and Skin Care, Interventional Urology and Voice and
Respiratory Care.
The Coloplast logo is a registered trademark of Coloplast A/S. ©
2023-11.
All rights reserved Coloplast A/S, 3050 Humlebaek, Denmark.
- Annual Report 2022-23
- Remuneration Report 2022-23
- Coloplast-2023-09-30-en
Coloplast AS (TG:CBHD)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Coloplast AS (TG:CBHD)
Historical Stock Chart
Von Mai 2023 bis Mai 2024